View Filing Data

Document and Entity Information - USD ($) $ in Thousands	6 Months Ended
Document and Entity Information - USD ($) $ in Thousands	Jun. 30, 2012	Jul. 31, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	Emergent BioSolutions Inc.
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float	$ 0
Entity Common Stock, Shares Outstanding		36,203,917
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2012

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 161,843	$ 143,901
Investments	0	1,966
Accounts receivable	46,815	74,153
Inventories	16,008	14,661
Deferred tax assets, net	638	1,735
Income tax receivable, net	10,422	9,506
Restricted cash	0	220
Prepaid expenses and other current assets	7,489	8,276
Total current assets	243,215	254,418
Property, plant and equipment, net	224,894	208,973
In-process research and development	41,800	51,400
Goodwill	5,502	5,502
Assets held for sale	0	11,765
Deferred tax assets, net	11,016	13,999
Other assets	713	807
Total assets	527,140	546,864
Current liabilities:
Accounts payable	23,301	40,530
Accrued expenses and other current liabilities	1,623	1,170
Accrued compensation	13,980	20,884
Contingent value rights, current portion	0	1,748
Long-term indebtedness, current portion	4,057	5,360
Deferred revenue	1,504	1,362
Total current liabilities	44,465	71,054
Contingent value rights, net of current portion	0	3,005
Long-term indebtedness, net of current portion	58,140	54,094
Other liabilities	2,013	1,984
Total liabilities	104,618	130,137
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 36,203,917 and 36,002,698 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively	36	36
Additional paid-in capital	225,231	220,654
Accumulated other comprehensive loss	(3,249)	(3,313)
Retained earnings	197,670	196,869
Total Emergent BioSolutions Inc. stockholders' equity	419,688	414,246
Noncontrolling interest in subsidiaries	2,834	2,481
Total stockholders' equity	422,522	416,727
Total liabilities and stockholders' equity	$ 527,140	$ 546,864

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2012	Dec. 31, 2011
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	36,203,917	36,002,698
Common stock, shares outstanding (in shares)	36,203,917	36,002,698

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenues:
Product sales	$ 53,161	$ 71,479	$ 87,518	$ 77,076
Contracts and grants	17,218	16,662	33,172	29,598
Total revenues	70,379	88,141	120,690	106,674
Operating expenses:
Cost of product sales	13,186	16,069	20,697	17,137
Research and development	30,645	31,481	56,891	66,240
Selling, general and administrative	17,895	20,384	37,387	38,596
Impairment of in-process research and development	0	0	9,600	0
Income (loss) from operations	8,653	20,207	(3,885)	(15,299)
Other income (expense):
Interest income	29	24	54	59
Interest expense	0	(6)	(6)	(6)
Other income (expense), net	907	(39)	1,761	(40)
Total other income (expense)	936	(21)	1,809	13
Income (loss) before provision for (benefit from) income taxes	9,589	20,186	(2,076)	(15,286)
Provision for (benefit from) income taxes	4,043	7,663	403	(4,636)
Net income (loss)	5,546	12,523	(2,479)	(10,650)
Net loss attributable to noncontrolling interest	2,086	1,687	3,279	3,463
Net income (loss) attributable to Emergent BioSolutions Inc.	$ 7,632	$ 14,210	$ 800	$ (7,187)
Income (loss) per share - basic (in dollars per share)	$ 0.21	$ 0.40	$ 0.02	$ (0.2)
Income (loss) per share - diluted (in dollars per share)	$ 0.21	$ 0.39	$ 0.02	$ (0.2)
Weighted-average number of shares - basic (in shares)	36,182,826	35,619,514	36,114,400	35,400,906
Weighted-average number of shares - diluted (in shares)	36,556,697	36,667,452	36,301,335	35,400,906

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Comprehensive Income [Abstract]
Net income (loss) attributable to Emergent BioSolutions Inc.	$ 7,632	$ 14,210	$ 800	$ (7,187)
Foreign currency translations	(20)	31	64	(662)
Comprehensive income (loss)	$ 7,612	$ 14,241	$ 864	$ (7,849)

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the economic entity, including both controlling (parent) and noncontrolling interests. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, including any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net loss	$ (2,479)	$ (10,650)
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	5,425	5,150
Depreciation and amortization	4,909	4,514
Deferred income taxes	4,080	3,129
Non-cash development expenses from joint ventures	3,632	3,348
Change in fair value of contingent value rights	(3,005)	1,408
Impairment of in-process research and development	9,600	0
Impairment of long-lived assets	0	193
Excess tax benefits from stock-based compensation	1,247	(1,786)
Other	(55)	43
Changes in operating assets and liabilities:
Accounts receivable	27,338	(7,937)
Inventories	(1,347)	(4,540)
Income taxes	(2,163)	(8,408)
Prepaid expenses and other assets	888	1,401
Accounts payable	(7,068)	(1,143)
Accrued expenses and other liabilities	488	3
Accrued compensation	(6,900)	(10,160)
Deferred revenue	142	(3,973)
Net cash provided by (used in) operating activities	34,732	(29,408)
Cash flows from investing activities:
Purchases of property, plant and equipment	(30,921)	(16,795)
Proceeds from sale of assets	11,765	0
Proceeds from maturity of investments	1,966	2,250
Purchase of investments	0	(5,269)
Net cash used in investing activities	(17,190)	(19,814)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	11,413	0
Issuance of common stock subject to exercise of stock options	401	8,695
Excess tax benefits from stock-based compensation	(1,247)	1,786
Principal payments on long-term indebtedness and line of credit	(8,670)	(8,123)
Contingent value right payment	(1,748)	0
Release of restricted cash deposit	220	0
Net cash provided by (used in) financing activities	369	2,358
Effect of exchange rate changes on cash and cash equivalents	31	(61)
Net increase (decrease) in cash and cash equivalents	17,942	(46,925)
Cash and cash equivalents at beginning of period	143,901	169,019
Cash and cash equivalents at end of period	$ 161,843	$ 122,094

Basis of presentation and consolidation	6 Months Ended
Basis of presentation and consolidation	Jun. 30, 2012
Basis of presentation and consolidation
Basis of presentation and consolidation	1. Basis of presentation and consolidation The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2012 and the results of operations, comprehensive income (loss) and cash flows for the three and six months ended June 30, 2012 and 2011. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. In June 2011, the Financial Accounting Standard Board ("FASB") issued guidance amending the presentation requirements for comprehensive income. For public entities, this guidance was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 with early adoption permitted. Subsequently, in December 2011, the FASB deferred the effective date of the portion of the June 2011 accounting standards update requiring separate presentation of reclassifications out of accumulated other comprehensive income (loss). Upon adoption on January 1, 2012, the Company had the option to report total comprehensive income (loss), including components of net income (loss) and components of other comprehensive income (loss), as a single continuous statement or in two separate but consecutive statements. The Company elected to present comprehensive income in two separate but consecutive statements as part of the consolidated financial statements included in this Quarterly Report on Form 10-Q.

Fair value measurements

6 Months Ended

Jun. 30, 2012

Fair value measurements [Abstract]

Fair value measurements

2. Fair value measurements

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At June 30, 2012
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	55,612	$	-	$	-	$	55,612
Total assets		$	55,612	$	-	$	-	$	55,612

	At December 31, 2011
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	73,005	$	-	$	-	$	73,005
U.S. Treasury securities (2)			-		1,966		-		1,966
Total assets		$	73,005	$	1,966	$	-	$	74,971

Liabilities:
Contingent value rights		$	-	$	-	$	4,753	$	4,753
Total liabilities		$	-	$	-	$	4,753	$	4,753

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

(2) Included in investments in accompanying consolidated balance sheets.

As of June 30, 2012 and 2011, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.

The fair value of the contingent value right ("CVR") obligations is based on management's assessment of certain development and collaboration milestones, which are inputs that have no observable market (Level 3). The obligation is measured using a discounted cash flow model. For the three and six months ended June 30, 2012 and 2011, the changes in the fair value of the CVR obligations resulted from an update to the probability and estimated timing of achievement for certain development milestones along with an adjustment to the discount rates.

For the three months ended June 30, 2012, the Company recorded no adjustment to the fair value of the CVR obligations. For the six months ended June 30, 2012, the Company recorded decreases in the CVR obligations of $3.0 million due to notification from Pfizer Inc. ("Pfizer") of Pfizer's intent to cease development of programs related to the CVR milestones and a $1.7 million payment related to the Company's collaboration with Abbott Laboratories ("Abbott"). For the three and six months ended June 30, 2011, the Company recorded an increase in the fair value of the CVR obligations of $827,000 and $1.4 million, respectively. The adjustments to fair value are classified in the Company's statements of operations as research and development expense within the Company's Biosciences segment.

The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2012 and the year ended December 31, 2011.

(in thousands)
Balance at January 1, 2011	$	14,532
Expense (income) included in earnings		221
Expense (income) included in comprehensive income (loss)		-
Settlements		(10,000	)
Purchases, sales, issuances and settlements		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2011	$	4,753
Expense (income) included in earnings		(3,005	)
Expense (income) included in comprehensive income (loss)		-
Settlements		(1,748	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at June 30, 2012	$	-

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. During the six months ended June 30, 2012, the Company's SBI-087 in-process research and development ("IPR&D") asset and goodwill were measured at fair value on a nonrecurring basis, as a result of the notification from Pfizer of its intent to cease development on the SBI-087 program and the Company's intent not to pursue further development of this asset. As of June 30, 2012, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.

Both the carrying value and fair value of long-term indebtedness at June 30, 2012 and December 31, 2011 were $62.2 million and $59.5 million, respectively.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventories

6 Months Ended

Jun. 30, 2012

Inventories [Abstract]

Inventories

3. Inventories

Inventories consist of the following:

	June 30,		December 31,
(in thousands)		2012		2011
Raw materials and supplies	$	2,740	$	2,313
Work-in-process		9,572		10,149
Finished goods		3,696		2,199
Total inventories	$	16,008	$	14,661

In-Process Research and Development and Goodwill	6 Months Ended
In-Process Research and Development and Goodwill	Jun. 30, 2012
In-Process Research and Development and Goodwill [Abstract]
In-Process Research and Development and Goodwill	4. In-process research and development and goodwill During the six months ended June 30, 2012, Pfizer notified the Company of its intent to terminate its current development programs with respect to the Company's SBI-087 product candidate. The Company considered the notification as a potential indicator of impairment of the related SBI-087 IPR&D asset, and as a result assessed the fair value of this asset. As part of the assessment, the Company considered the impact of Pfizer's decision, along with the Company's intent not to pursue further development of this asset. As a result of the impairment analysis, the Company recorded an impairment charge of $9.6 million during the during the six months ended June 30, 2012, which represented the entire carrying value of the SBI-087 IPR&D. This charge is classified in the Company's statements of operations as impairment of in-process research and development, within the Company's Biosciences segment. The Company determined the fair value of the SBI-087 IPR&D asset by utilizing an income approach. The Company's cash flow projections include management's estimates related to the costs to develop the acquired technology into commercially viable products, the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and cost projections were adjusted to reflect the probability of successful new drug development. Additionally, the projections considered the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions. The rates utilized to discount the net cash flows to their present value were commensurate with the stage of development of the SBI-087 product candidate and uncertainties in the economic estimates used in the projections described above. As a result of the impairment of the SBI-087 IPR&D asset, the Company also performed an interim impairment analysis of the Biosciences therapeutic reporting unit, which contains all goodwill reported on the Company's consolidated balance sheets as of June 30, 2012. Based on the interim impairment assessment, the estimated fair value of the Biosciences therapeutic reporting unit was in excess of carrying value, and therefore no impairment of goodwill was recorded.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Assets held for sale	6 Months Ended
Assets held for sale	Jun. 30, 2012
Assets held for sale [Abstract]
Assets held for sale	5. Assets held for sale During the six months ended June 30, 2012, the Company completed the sale of two buildings in Frederick, Maryland for $12.2 million. These buildings had been classified as assets held for sale. The Company realized proceeds equal to the carrying value, less cost to sell, of these buildings and there was no gain or loss on the sale.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Long-term debt

6 Months Ended

Jun. 30, 2012

Long-Term Debt [Abstract]

Long-term debt

6. Long-term debt

The components of long-term indebtedness are as follows:

	June 30,			December 31,
(in thousands)		2012			2011
Construction loan dated July 2011; LIBOR plus 3%, due July 2017	$	30,000		$	26,095
Equipment loan dated August 2011; variable, due December 2017		8,935			1,426
Term loan dated December 2009; three month LIBOR plus 3.25%, due December 2014		18,958			19,717
Term loan dated November 2009; three month LIBOR plus 3.25%, due November 2014		4,304			4,478
Loan dated October 2004; 3.0%, repaid in March 2012		-			2,500
Term loan dated October 2004; 3.48%, repaid in March 2012		-			5,238
Total long-term indebtedness		62,197			59,454
Less current portion of long-term indebtedness		(4,057	)		(5,360	)
Noncurrent portion of long-term indebtedness	$	58,140		$	54,094

On June 28, 2012, the Company amended the financial covenants of the construction loan and the equipment loan with PNC Bank to include a revised definition of earnings before income taxes, depreciation and amortization that excludes certain non-cash charges. As of June 30, 2012, the Company was in compliance with all debt covenenants.

On July 11, 2012, the Company amended the equipment loan with PNC to extend the drawdown period to December 15, 2012 and extend the maturity date of the loan from July 2017 to December 2017.

Stockholders' equity

6 Months Ended

Jun. 30, 2012

Stock options and restricted stock units [Abstract]

Stock options and restricted stock units

7. Stockholders' equity

Preferred stock

The Company is authorized to issue up to 15,000,000 shares of preferred stock, $0.001 par value per share ("Preferred Stock"). Any Preferred Stock issued may have dividend rates, voting rights, conversion privileges, redemption characteristics, and sinking fund requirements as approved by the Company's board of directors.

Common stock

The Company currently has one class of $0.001 par value per share common stock ("Common Stock") authorized and outstanding. The Company is authorized to issue up to 100,000,000 shares of Common Stock. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters, except as may be provided by law.

Stock options and restricted stock units

As of June 30, 2012, the Company had two stock-based employee compensation plans, the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan") (together, the "Emergent Plans"). The Company has granted options to purchase shares of common stock under the Emergent Plans and has granted restricted stock units under the 2006 Plan. The Emergent Plans have both incentive and non-qualified stock option features. The Company no longer grants equity awards under the 2004 Plan.

On May 17, 2012, the Company's shareholders approved the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 2,500,000. As of June 30, 2012, an aggregate of 11,178,826 shares of common stock were authorized for issuance under the 2006 Plan, of which a total of 3,757,296 shares of common stock remain available for future awards to be made to plan participants. As part of the May 2012 amendment, awards of restricted stock units after May 17, 2012 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 1.86 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 287,700. The exercise price of each option must be not less than 100% of the fair market value of the shares underlying such option on the date of grant. Awards granted under the 2006 Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plans are determined by the compensation committee of the Company's board of directors, which administers the Emergent Plans. Each equity award granted under the Emergent Plans vests as specified in the relevant agreement with the award recipient and no option can be exercised after ten years from the date of grant.

The following is a summary of option award activity under the Emergent Plans:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2011		3,090,909		$	17.35		53,156	$	8.86	$	6,238,427
Granted		726,291			15.75		-		-
Exercised		(43,491	)		9.23		-		-
Forfeited		(125,678	)		19.52		-		-
Outstanding at June 30, 2012		3,648,031		$	17.06		53,156	$	8.86	$	4,227,300
Exercisable at June 30, 2012		2,176,650		$	16.09		53,156	$	8.86	$	4,200,518

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2011		635,500		$	20.89	$	10,714,450
Granted		363,197			15.75
Vested		(228,369	)		20.26
Forfeited		(33,545	)		20.10
Outstanding at June 30, 2012		736,783		$	18.58	$	11,162,262

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Variable interest entities

6 Months Ended

Jun. 30, 2012

Variable interest entities [Abstract]

Variable interest entities

8. Variable interest entities

In July 2008, the Company entered into a collaboration with the University of Oxford ("Oxford") and certain Oxford researchers to conduct clinical trials to advance a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). The Company has a 51% equity interest in OETC and controls the OETC Board of Directors. In addition, the Company has certain funding and service obligations related to its investment. In July 2011, the Company entered into an intercompany loan agreement with OETC, under which the Company agreed to provide OETC with a loan of up to $14.0 million to fund future clinical and development costs for the tuberculosis vaccine product candidate. The loan value can be increased to up to $23.0 million at the sole discretion of the Company. The loan bears interest at the rate of 8% per annum. Principal and interest on the outstanding balance will be due and payable in December 2014 or upon occurrence of either an event of default or the closing of a debt or equity financing by OETC that results in net proceeds equal to or in excess of $30.0 million in a single transaction or a series of related transactions. Under the terms of the loan, OETC is required to comply with certain non-financial covenants. As of June 30, 2012, OETC was in compliance with all non-financial covenants. As of June 30, 2012, $4.0 million has been drawn by OETC under the loan facility. The Company evaluates its variable interests in OETC on a quarterly basis and has determined that it is the primary beneficiary as it has the power to direct the activities of OETC that most significantly impact OETC's economic performance and will absorb the majority of expected losses. Accordingly, the Company consolidates OETC. As of June 30, 2012 and 2011, respectively, assets of $3.5 million and $394,000 and liabilities of $5.3 million and $910,000 related to OETC were included within the Company's consolidated balance sheets. During the three and six months ended June 30, 2012, respectively, OETC incurred net losses of $4.2 million and $6.5 million, of which $2.1 million and $3.3 million are included in the Company's consolidated statements of operations. During the three and six months ended June 30, 2011, respectively, OETC incurred net losses of $3.2 million and $6.8 million, of which $1.6 million and $3.4 million are included in the Company's consolidated statements of operations.

In conjunction with the establishment of OETC, the Company granted a put option to Oxford and certain Oxford researchers whereby the Company may be required to acquire all of the OETC shares held by Oxford and the Oxford researchers at the fair market value of the underlying shares. This put option is contingent upon the satisfaction of a number of conditions that must exist or occur subsequent to the granting by the European Commission of marketing authorization for the OETC-sponsored vaccine product candidate for tuberculosis. The Company accounts for the put option in accordance with the accounting provisions related to derivatives and distinguishing liabilities from equity. In accordance with these provisions, the Company has determined that the put option had a de minimis fair value as of June 30, 2012.

In July 2010, the Company entered into a collaboration with Temasek Life Sciences Ventures Pte Limited to advance the development of vaccine and monoclonal products for worldwide prophylaxis or treatment of infection caused by existing or anticipated future pandemic influenza strains via a hemagglutinin-based medical countermeasure, resulting in the formation of EPIC Bio Pte Limited ("EPIC"). The Company has a 60% equity interest in EPIC and controls the EPIC Board of Directors. The Company evaluates its variable interests in EPIC on a quarterly basis and has determined that it is the primary beneficiary as it has the power to direct the activities of EPIC that most significantly impact EPIC's economic performance and will absorb the majority of expected losses. Accordingly, the Company consolidates EPIC. As of June 30, 2012 and 2011, respectively, assets of $317,000 and $1.9 million and liabilities of $99,000 and $741,000 related to EPIC were included within the Company's consolidated balance sheets. During the three and six months ended June 30, 2012, respectively, EPIC incurred net losses of $111,000 and $210,000, of which $67,000 and $126,000 are included in the Company's consolidated statements of operations. During the three and six months ended June 30, 2011, EPIC incurred net losses of $352,000 and $375,000, respectively, of which $211,000 and $225,000 are included in the Company's consolidated statements of operations.

The following is a summary of the stockholders' equity attributable to the Company and the noncontrolling interests:

	Emergent		Noncontrolling
(in thousands)	BioSolutions Inc.		Interests			Total
Stockholders' equity at December 31, 2011	$	414,246	$	2,481		$	416,727
Non-cash development expenses from variable interest entities		-		3,632			3,632
Net income (loss)		800		(3,279	)		(2,479	)
Other		4,642		-			4,642
Stockholders' equity at June 30, 2012	$	419,688	$	2,834		$	422,522

- Definition

The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.

+ References + Details

Collaboration Agreements	6 Months Ended
Collaboration Agreements	Jun. 30, 2012
Collaboration Agreements [Abstract]
Collaboration Agreements	9. Collaboration agreements Abbott Laboratories In August 2009, Trubion Pharmaceuticals, Inc. ("Trubion"), which the Company acquired in October 2010, entered into a collaboration agreement with Facet Biotech Corporation, now a wholly-owned subsidiary of Abbott, for the joint worldwide development and commercialization of TRU-016. The collaboration agreement covered TRU-016 in all indications and all other CD37-directed protein therapeutics. The collaboration agreement terminated on March 20, 2012 and all rights to TRU-016 and other CD37-directed protein therapeutics under the collaboration agreement reverted back to the Company. During the three and six months ended June 30, 2012, the Company recognized revenue of $1.4 million and $2.7 million, respectively, for research and development services pursuant to the Abbott collaboration, which are included in the Company's statements of operations as contracts and grants revenue within the Company's Biosciences segment. Pfizer Inc. In December 2005, Trubion entered into an agreement (the "Pfizer Agreement") with Wyeth Pharmaceuticals, now a wholly-owned subsidiary of Pfizer, for the development and worldwide commercialization of CD20-directed therapeutics. In May 2011, the Company and Pfizer entered into a third amendment to the Pfizer Agreement (the "Biosimilar Amendment") in which the Company released certain restrictions related to the development and commercialization of biosimilar CD20 antibodies. Under the terms of this amendment, the Company received a $2.5 million non-refundable payment upon execution of the Biosimilar Amendment, and is entitled to receive royalty payments in the low-single digits on net sales of certain Pfizer biosimilar products directed to CD20, subject to the satisfaction of specified conditions. In April 2012, Pfizer notified the Company of its intent to terminate the Pfizer Agreement, and in June 2012 the Company received formal written notice of termination of the Pfizer Agreement. The Company's right to receive royalty payments under the Biosimiliar Amendment survives termination of the Pfizer Agreement. For the three and six months ended June 30, 2012, the Company recognized revenue of $512,000 and $877,000, respectively, for research and development services pursuant to the Pfizer Agreement, which are included in the Company's statements of operations as contracts and grants revenue within the Company's Biosciences segment.

Business Interruption Insurance Recovery	6 Months Ended
Business Interruption Insurance Recovery	Jun. 30, 2012
Business Interruption Insurance Recovery [Abstract]
Business Interruption Insurance Recovery [Text Block]	10. Business interruption insurance recovery During the six months ended June 30, 2012, the Company recorded $1.7 million in insurance recovery related to a power outage at its Lansing, Michigan facility. The insurance recovery is classified in the Company's statements of operations as other income (expense), net.

Earnings per share

6 Months Ended

Jun. 30, 2012

Earnings per share [Abstract]

Earnings per share

11.Earnings per share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands, except share and per share data)		2012		2011		2012		2011
Numerator:
Net income (loss)	$	7,632	$	14,210	$	800	$	(7,187	)

Denominator:
Weighted-average number of shares-basic		36,182,826		35,619,514		36,114,400		35,400,906
Dilutive securities-equity awards		373,871		1,047,938		186,935		-
Weighted-average number of shares-diluted		36,556,697		36,667,452		36,301,335		35,400,906

Income (loss) per share-basic	$	0.21	$	0.40	$	0.02	$	(0.20	)
Income (loss) per share-diluted	$	0.21	$	0.39	$	0.02	$	(0.20	)

Stock options with exercise prices in excess of the average per share closing price during the period are not considered in the calculation of fully diluted earnings per share. For the three month periods ended June 30, 2012 and 2011, approximately 3.0 million and 719,000 stock options, respectively, and 3.0 million stock options for the six month period ended June 30, 2012 were excluded from the calculation. These stock options were excluded because the exercise prices were in excess of the average per share closing price.

For the six month period ended June 30, 2011, approximately 4.0 million shares pursuant to equity awards were excluded from the calculation of diluted earnings per share because the net loss attributable to Emergent BioSolutions Inc. would make these awards antidilutive.

Segment information

6 Months Ended

Jun. 30, 2012

Segment information [Abstract]

Segment information

12. Segment information

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is reviewed by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different development processes.

In the Biodefense division, the Company develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. In the Biosciences division, the Company develops vaccines, protein therapeutics and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs. The Biosciences division consists of two business units, therapeutics and vaccines, and is comprised of development stage product candidates. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences. The assets in this segment consist primarily of cash.

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Three Months Ended June 30, 2012
External revenue	$	66,964	$	3,415		$	-		$	70,379
Net income (loss)		24,335		(14,963	)		(1,740	)		7,632
Total assets		257,377		129,565			140,198			527,140
Three Months Ended June 30, 2011
External revenue	$	83,685	$	4,456		$	-		$	88,141
Net income (loss)		36,902		(20,580	)		(2,112	)		14,210
Total assets		217,057		121,209			155,718			493,984

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Six Months Ended June 30, 2012
External revenue	$	115,600	$	5,090		$	-		$	120,690
Net income (loss)		38,601		(34,854	)		(2,947	)		800
Total assets		257,377		129,565			140,198			527,140
Six Months Ended June 30, 2011
External revenue	$	99,185	$	7,489		$	-		$	106,674
Net income (loss)		30,810		(35,705	)		(2,292	)		(7,187	)
Total assets		217,057		121,209			155,718			493,984

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Basis of presentation and consolidation (Policies)	6 Months Ended
Basis of presentation and consolidation (Policies)	Jun. 30, 2012
Basis of presentation and consolidation
Basis of presentation and consolidation	The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2012 and the results of operations, comprehensive income (loss) and cash flows for the three and six months ended June 30, 2012 and 2011. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. In June 2011, the Financial Accounting Standard Board ("FASB") issued guidance amending the presentation requirements for comprehensive income. For public entities, this guidance was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 with early adoption permitted. Subsequently, in December 2011, the FASB deferred the effective date of the portion of the June 2011 accounting standards update requiring separate presentation of reclassifications out of accumulated other comprehensive income (loss). Upon adoption on January 1, 2012, the Company had the option to report total comprehensive income (loss), including components of net income (loss) and components of other comprehensive income (loss), as a single continuous statement or in two separate but consecutive statements. The Company elected to present comprehensive income in two separate but consecutive statements as part of the consolidated financial statements included in this Quarterly Report on Form 10-Q.

Fair value measurements (Tables)

6 Months Ended

Jun. 30, 2012

Fair value measurements [Abstract]

Fair value of financial assets and liabilities

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At June 30, 2012
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	55,612	$	-	$	-	$	55,612
Total assets		$	55,612	$	-	$	-	$	55,612

	At December 31, 2011
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	73,005	$	-	$	-	$	73,005
U.S. Treasury securities (2)			-		1,966		-		1,966
Total assets		$	73,005	$	1,966	$	-	$	74,971

Liabilities:
Contingent value rights		$	-	$	-	$	4,753	$	4,753
Total liabilities		$	-	$	-	$	4,753	$	4,753

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

(2) Included in investments in accompanying consolidated balance sheets.

Unobservable inputs reconciliation

(in thousands)
Balance at January 1, 2011	$	14,532
Expense (income) included in earnings		221
Expense (income) included in comprehensive income (loss)		-
Settlements		(10,000	)
Purchases, sales, issuances and settlements		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2011	$	4,753
Expense (income) included in earnings		(3,005	)
Expense (income) included in comprehensive income (loss)		-
Settlements		(1,748	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at June 30, 2012	$	-

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

Inventories (Tables)

6 Months Ended

Jun. 30, 2012

Inventories [Abstract]

Inventories

Inventories consist of the following:

	June 30,		December 31,
(in thousands)		2012		2011
Raw materials and supplies	$	2,740	$	2,313
Work-in-process		9,572		10,149
Finished goods		3,696		2,199
Total inventories	$	16,008	$	14,661

Long-term debt (Tables)

6 Months Ended

Jun. 30, 2012

Long-Term Debt [Abstract]

Components of long-term indebtedness

The components of long-term indebtedness are as follows:

	June 30,			December 31,
(in thousands)		2012			2011
Construction loan dated July 2011; LIBOR plus 3%, due July 2017	$	30,000		$	26,095
Equipment loan dated August 2011; variable, due December 2017		8,935			1,426
Term loan dated December 2009; three month LIBOR plus 3.25%, due December 2014		18,958			19,717
Term loan dated November 2009; three month LIBOR plus 3.25%, due November 2014		4,304			4,478
Loan dated October 2004; 3.0%, repaid in March 2012		-			2,500
Term loan dated October 2004; 3.48%, repaid in March 2012		-			5,238
Total long-term indebtedness		62,197			59,454
Less current portion of long-term indebtedness		(4,057	)		(5,360	)
Noncurrent portion of long-term indebtedness	$	58,140		$	54,094

Stockholders' equity (Tables)

6 Months Ended

Jun. 30, 2012

Stock options and restricted stock units [Abstract]

Option award activity

The following is a summary of option award activity under the Emergent Plans:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2011		3,090,909		$	17.35		53,156	$	8.86	$	6,238,427
Granted		726,291			15.75		-		-
Exercised		(43,491	)		9.23		-		-
Forfeited		(125,678	)		19.52		-		-
Outstanding at June 30, 2012		3,648,031		$	17.06		53,156	$	8.86	$	4,227,300
Exercisable at June 30, 2012		2,176,650		$	16.09		53,156	$	8.86	$	4,200,518

Restricted stock units activity

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2011		635,500		$	20.89	$	10,714,450
Granted		363,197			15.75
Vested		(228,369	)		20.26
Forfeited		(33,545	)		20.10
Outstanding at June 30, 2012		736,783		$	18.58	$	11,162,262

Variable interest entities (Tables)

6 Months Ended

Jun. 30, 2012

Variable interest entities [Abstract]

Stockholders equity

The following is a summary of the stockholders' equity attributable to the Company and the noncontrolling interests:

	Emergent		Noncontrolling
(in thousands)	BioSolutions Inc.		Interests			Total
Stockholders' equity at December 31, 2011	$	414,246	$	2,481		$	416,727
Non-cash development expenses from variable interest entities		-		3,632			3,632
Net income (loss)		800		(3,279	)		(2,479	)
Other		4,642		-			4,642
Stockholders' equity at June 30, 2012	$	419,688	$	2,834		$	422,522

Earnings per share (Tables)

6 Months Ended

Jun. 30, 2012

Earnings per share [Abstract]

Summary of basic and diluted net income per share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands, except share and per share data)		2012		2011		2012		2011
Numerator:
Net income (loss)	$	7,632	$	14,210	$	800	$	(7,187	)

Denominator:
Weighted-average number of shares-basic		36,182,826		35,619,514		36,114,400		35,400,906
Dilutive securities-equity awards		373,871		1,047,938		186,935		-
Weighted-average number of shares-diluted		36,556,697		36,667,452		36,301,335		35,400,906

Income (loss) per share-basic	$	0.21	$	0.40	$	0.02	$	(0.20	)
Income (loss) per share-diluted	$	0.21	$	0.39	$	0.02	$	(0.20	)

Segment information (Tables)

6 Months Ended

Jun. 30, 2012

Segment information [Abstract]

Segment information

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Three Months Ended June 30, 2012
External revenue	$	66,964	$	3,415		$	-		$	70,379
Net income (loss)		24,335		(14,963	)		(1,740	)		7,632
Total assets		257,377		129,565			140,198			527,140
Three Months Ended June 30, 2011
External revenue	$	83,685	$	4,456		$	-		$	88,141
Net income (loss)		36,902		(20,580	)		(2,112	)		14,210
Total assets		217,057		121,209			155,718			493,984

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Six Months Ended June 30, 2012
External revenue	$	115,600	$	5,090		$	-		$	120,690
Net income (loss)		38,601		(34,854	)		(2,947	)		800
Total assets		257,377		129,565			140,198			527,140
Six Months Ended June 30, 2011
External revenue	$	99,185	$	7,489		$	-		$	106,674
Net income (loss)		30,810		(35,705	)		(2,292	)		(7,187	)
Total assets		217,057		121,209			155,718			493,984

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Fair value measurements (Details) - USD ($)
$ in Thousands

6 Months Ended

12 Months Ended

Jun. 30, 2012

Dec. 31, 2011

Unobservable Input Reconciliation [Roll Forward]

Balance beginning of period

$ 4,753

$ 14,532

Expense (income) included in earnings

(3,005)

221

Expense (income) included in Comprehensive Income

Settlements

(1,748)

(10,000)

Purchases, sales, issuances and settlements

Transfers in/(out) of Level 3

Balance End of period

4,753

Long-term indebtedness [Abstract]

Carrying value long-term indebtedness

62,197

59,454

Fair value of long-term indebtedness

62,200

59,500

Fair Value, Measurements, Recurring [Member]

Assets:

Investment in money market funds

^[1]

55,612

73,005

U.S. Treasury securities

^[2]

1,966

Total assets

55,612

74,971

Liabilities:

Contingent value rights

4,753

Total liabilities

4,753

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]

Assets:

Investment in money market funds

^[1]

55,612

73,005

U.S. Treasury securities

^[2]

Total assets

55,612

73,005

Liabilities:

Contingent value rights

Total liabilities

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]

Assets:

Investment in money market funds

^[1]

U.S. Treasury securities

^[2]

1,966

Total assets

1,966

Liabilities:

Contingent value rights

Total liabilities

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]

Assets:

Investment in money market funds

^[1]

U.S. Treasury securities

^[2]

Total assets

$ 0

Liabilities:

Contingent value rights

4,753

Total liabilities

$ 4,753

[1]	Included in cash and cash equivalents in accompanying consolidated balance sheets.
[2]	Included in investments in accompanying consolidated balance sheets.

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Inventories [Abstract]
Raw materials and supplies	$ 2,740	$ 2,313
Work-in-process	9,572	10,149
Finished goods	3,696	2,199
Total inventories	$ 16,008	$ 14,661

In-Process Research and Development and Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
In-Process Research and Development and Goodwill [Abstract]
Research and Development in Process	$ 0	$ 0	$ 9,600	$ 0

Assets held for sale (Details) $ in Millions	6 Months Ended
Assets held for sale (Details) $ in Millions	Jun. 30, 2012 USD ($)
Assets held for sale [Abstract]
Sales price of asset held for sale	$ 12.2

Long-term debt (Details) - USD ($) $ in Thousands	6 Months Ended
Long-term debt (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Long-Term Debt [Line Items]
Carrying value long-term indebtedness	$ 62,197	$ 59,454
Long-term indebtedness, current portion	(4,057)	(5,360)
Long-term indebtedness, net of current portion	58,140	54,094
Construction Loan [Member]
Long-Term Debt [Line Items]
Carrying value long-term indebtedness	$ 30,000	26,095
Maturity date	Jul. 15, 2017
Description of variable rate basis	LIBOR plus
Interest rate, stated percentage (in hundredths)	3.00%
Equipment Loan [Member]
Long-Term Debt [Line Items]
Carrying value long-term indebtedness	$ 8,935	1,426
Maturity date	Dec. 15, 2017
Description of variable rate basis	variable
Term Loan December 2009 [Member]
Long-Term Debt [Line Items]
Carrying value long-term indebtedness	$ 18,958	19,717
Maturity date	Dec. 15, 2014
Description of variable rate basis	three month LIBOR plus
Interest rate, stated percentage (in hundredths)	3.25%
Term Loan November 2009 [Member]
Long-Term Debt [Line Items]
Carrying value long-term indebtedness	$ 4,304	4,478
Maturity date	Nov. 15, 2014
Description of variable rate basis	three month LIBOR plus
Interest rate, stated percentage (in hundredths)	3.25%
Loan Dated October 2004 [Member]
Long-Term Debt [Line Items]
Carrying value long-term indebtedness	$ 0	2,500
Maturity date	Mar. 15, 2012
Interest rate, stated percentage (in hundredths)	3.00%
Term Loan October 2004 [Member]
Long-Term Debt [Line Items]
Carrying value long-term indebtedness	$ 0	$ 5,238
Maturity date	Mar. 15, 2012
Interest rate, stated percentage (in hundredths)	3.48%

Stockholders' equity (Details)	6 Months Ended
Stockholders' equity (Details)	Jun. 30, 2012 USD ($) $ / shares shares	Jun. 30, 2012 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock based employee compensation plans		2
Common stock authorized for issuance under the plan (in shares)		11,178,826
Common stock available for future awards (in shares)		3,757,296
Restricted stock unit conversion ratio		1.86
Maximum number of shares that may be granted per year to a single participant (in shares)	287,700
Share Based Compensation Arrangement by share Based Payment Award, Contractual life of awards	10 years
Stock Options [Member]
Aggregate Intrinsic Value [Abstract]
Outstanding Beginning of period \| $	$ 6,238,427
Outstanding End of period \| $	4,227,300
Exercisable End of period \| $	$ 4,200,518
2006 Plan [Member] \| Stock Options [Member]
Options outstanding [Roll Forward]
Outstanding beginning of period	3,090,909
Granted (in shares)	726,291
Exercised (in shares)	(43,491)
Forfeited (in shares)	(125,678)
Outstanding end of period	3,648,031
Exercisable end of period	2,176,650
Weighted-Average Exercise Price [Roll Forward]
Outstanding Beginning of period (in dollars per share) \| $ / shares	$ 17.35
Granted (in dollars per share) \| $ / shares	15.75
Exercised (in dollars per share) \| $ / shares	9.23
Forfeited (in dollars per share) \| $ / shares	19.52
Outstanding End of period (in dollars per share) \| $ / shares	17.06
Exercisable End of period (in dollars per share) \| $ / shares	$ 16.09
2006 Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Restricted stock unit award activity [Roll Forward]
Outstanding beginning of period (in shares)	635,500
Granted (in shares)	363,197
Vested (in shares)	(228,369)
Forfeited (in shares)	(33,545)
Outstanding end of period (in shares)	736,783
Weighted-Average Grant Price [Roll Forward]
Outstanding beginning of period (in dollars per share) \| $ / shares	$ 20.89
Granted (in dollars per share) \| $ / shares	15.75
Vested (in dollars per share) \| $ / shares	20.26
Forfeited (in dollars per share) \| $ / shares	20.10
Outstanding end of period (in dollars per share) \| $ / shares	$ 20.89	$ 18.58
Aggregate intrinsic value [Abstract]
Beginning of period \| $	$ 10,714,450
End of period \| $	$ 11,162,262
2004 Plan [Member] \| Stock Options [Member]
Options outstanding [Roll Forward]
Outstanding beginning of period	53,156
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding end of period	53,156
Exercisable end of period	53,156
Weighted-Average Exercise Price [Roll Forward]
Outstanding Beginning of period (in dollars per share) \| $ / shares	$ 8.86
Granted (in dollars per share) \| $ / shares	0
Exercised (in dollars per share) \| $ / shares	0
Forfeited (in dollars per share) \| $ / shares	0
Outstanding End of period (in dollars per share) \| $ / shares	8.86
Exercisable End of period (in dollars per share) \| $ / shares	$ 8.86

Variable interest entities (Details) - USD ($)	3 Months Ended		6 Months Ended
Variable interest entities (Details) - USD ($)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Variable Interest Entity [Line Items]
Net loss	$ 5,546,000	$ 12,523,000	$ (2,479,000)	$ (10,650,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity beginning of period			416,727,000
Non-cash development expenses from variable interest entities			3,632,000
Net income (loss)	5,546,000	12,523,000	(2,479,000)	(10,650,000)
Other			4,642,000
Stockholders' equity end of period	422,522,000		$ 422,522,000
Oxford-Emergent Tuberculosis Consortium [Member]
Variable Interest Entity [Line Items]
Ownership percentage of variable interest entity (in hundredths)			51.00%
Assets	3,500,000	394,000	$ 3,500,000	394,000
Liabilities	5,300,000	910,000	5,300,000	910,000
OETC Loan	4,000,000		4,000,000
Net loss	4,200,000	3,200,000	6,500,000	6,800,000
Net losses included in the Company's consolidated statement of operations	2,100,000	1,600,000	3,300,000	3,400,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	4,200,000	3,200,000	$ 6,500,000	6,800,000
EPIC Bio Pte Ltd [Member]
Variable Interest Entity [Line Items]
Ownership percentage of variable interest entity (in hundredths)			60.00%
Assets	317,000	1,900,000	$ 317,000	1,900,000
Liabilities	99,000	741,000	99,000	741,000
Net loss	111,000	352,000	210,000	375,000
Net losses included in the Company's consolidated statement of operations	67,000	211,000	126,000	225,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	111,000	$ 352,000	210,000	$ 375,000
Emergent BioSolutions Inc. [Member]
Variable Interest Entity [Line Items]
Net loss			800,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity beginning of period			414,246,000
Non-cash development expenses from variable interest entities			0
Net income (loss)			800,000
Other			4,642,000
Stockholders' equity end of period	419,688,000		419,688,000
Noncontrolling Interests [Member]
Variable Interest Entity [Line Items]
Net loss			(3,279,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity beginning of period			2,481,000
Non-cash development expenses from variable interest entities			3,632,000
Net income (loss)			(3,279,000)
Other			0
Stockholders' equity end of period	$ 2,834,000		$ 2,834,000

Collaboration Agreements (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Collaboration Agreements (Details) - USD ($)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Collaborative arrangements [Line Items]
Contracts and grants	$ 17,218,000	$ 16,662,000	$ 33,172,000	$ 29,598,000
Abbott Laboratories TRU016 [Member]
Collaborative arrangements [Line Items]
Contracts and grants	1,400,000		2,700,000
Pfizer CD20 [Member]
Collaborative arrangements [Line Items]
Contracts and grants	$ 512,000		$ 877,000		$ 2,500,000

Business Interruption Insurance Recovery (Details) $ in Millions	6 Months Ended
	Jun. 30, 2012 USD ($)
Business Interruption Insurance Recovery [Abstract]
BusinessInterruptionInsuranceRevenue	$ 1.7

Earnings per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Numerator:
Net income (loss)	$ 7,632	$ 14,210	$ 800	$ (7,187)
Denominator:
Weighted-average number of shares-basic (in shares)	36,182,826	35,619,514	36,114,400	35,400,906
Dilutive securities-equity awards (in shares)	373,871	1,047,938	186,935	0
Weighted-average number of shares-diluted (in shares)	36,556,697	36,667,452	36,301,335	35,400,906
Income (loss) per share-basic	$ 0.21	$ 0.40	$ 0.02	$ (0.2)
Income (loss) per share-diluted	$ 0.21	$ 0.39	$ 0.02	$ (0.2)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive shares excluded from calculation (in shares)	3,000,000	719,000	3,000,000	4,000,000

Segment information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Segment information (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Segment Reporting Information [Line Items]
Number of business segments			2
External revenue	$ 70,379	$ 88,141	$ 120,690	$ 106,674
Net income (loss) attributable to Emergent BioSolutions Inc.	7,632	14,210	800	(7,187)
Total assets	527,140	493,984	527,140	493,984	$ 546,864
Biodefense [Member]
Segment Reporting Information [Line Items]
External revenue	66,964	83,685	115,600	99,185
Net income (loss) attributable to Emergent BioSolutions Inc.	24,335	36,902	38,601	30,810
Total assets	257,377	217,057	257,377	217,057
Biosciences [Member]
Segment Reporting Information [Line Items]
External revenue	3,415	4,456	5,090	7,489
Net income (loss) attributable to Emergent BioSolutions Inc.	(14,963)	(20,580)	(34,854)	(35,705)
Total assets	129,565	121,209	129,565	121,209
All Other [Member]
Segment Reporting Information [Line Items]
External revenue	0	0	0	0
Net income (loss) attributable to Emergent BioSolutions Inc.	(1,740)	(2,112)	(2,947)	(2,292)
Total assets	$ 140,198	$ 155,718	$ 140,198	$ 155,718

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details